Prostate Health and ED Medications: Separating Clinical Fact from Online Fiction for Long-Term Users

For many American men, medications like sildenafil and tadalafil have become a routine part of life — taken weekly, sometimes daily, over the course of years or even decades. That kind of sustained pharmaceutical exposure naturally raises questions. Among the most common concerns urologists hear: Could these drugs affect my prostate? Do they interfere with PSA testing? And is there any link to prostate cancer?

The internet offers no shortage of alarming answers to those questions — most of them wrong. This article cuts through the noise, drawing on peer-reviewed research and clinical guidance to give long-term users a grounded, accurate picture of where the science actually stands.

What PDE5 Inhibitors Do — and Where the Prostate Fits In

Phosphodiesterase-5 (PDE5) inhibitors — the drug class that includes sildenafil (Viagra, generic), tadalafil (Cialis, generic), and vardenafil — work by relaxing smooth muscle tissue and widening blood vessels. The mechanism is well understood in the context of erectile function, but the prostate also contains smooth muscle tissue and PDE5 enzyme activity, which means these drugs do, in fact, interact with the gland.

That interaction is not inherently harmful. In fact, tadalafil carries an FDA-approved indication for benign prostatic hyperplasia (BPH) — the non-cancerous enlargement of the prostate that causes urinary symptoms in a large proportion of men over 50. At a daily dose of 5 mg, tadalafil has been shown in multiple randomized controlled trials to reduce urinary urgency, improve flow rate, and decrease symptom scores on validated scales like the International Prostate Symptom Score (IPSS).

In other words, for men dealing with both ED and BPH — a combination that is extremely common — a PDE5 inhibitor may simultaneously address both conditions. This dual benefit is one reason urologists increasingly view these medications as valuable long-term therapeutic tools rather than occasional-use options.

Does Long-Term Use Affect PSA Levels?

Prostate-specific antigen (PSA) testing is a cornerstone of prostate cancer screening in the United States. Elevated PSA levels can indicate cancer, but they can also reflect BPH, prostatitis, or recent sexual activity. The concern some men have is whether chronic PDE5 inhibitor use might artificially suppress or elevate PSA readings, thereby obscuring a meaningful result.

Several studies have examined this question. A notable analysis published in BJU International found that long-term daily tadalafil use was associated with a modest but statistically significant reduction in PSA levels — roughly 3 to 5 percent — compared to placebo. This reduction is thought to result from the drug's anti-inflammatory and smooth-muscle-relaxing effects on prostate tissue, not from any masking of cancer activity.

Clinically, a 3 to 5 percent reduction is unlikely to meaningfully distort screening results for most men, particularly when PSA velocity (the rate of change over time) is tracked rather than a single absolute number. Nonetheless, urologists advise informing your physician about all medications — including PDE5 inhibitors — before PSA testing so results can be interpreted in proper context.

The Cancer Question: What Research Actually Shows

This is where online misinformation is most rampant. Some forums and unvetted health blogs suggest that ED medications either cause prostate cancer or, conversely, protect against it. Neither claim is supported by robust clinical evidence.

A large-scale observational study published in Cancer Epidemiology, Biomarkers & Prevention followed tens of thousands of men over multiple years and found no statistically significant association between PDE5 inhibitor use and increased prostate cancer incidence. Separately, a cohort study from the Veterans Affairs health system — one of the largest databases of male health outcomes in the country — similarly found no elevated cancer risk attributable to these medications.

There is, however, an intriguing body of emerging research suggesting that PDE5 inhibitors may have mild anti-tumor properties in laboratory settings, owing to their effects on cellular proliferation pathways. This does not translate into a clinical cancer-prevention recommendation — the evidence is far too preliminary for that — but it does further undercut the narrative that these drugs are oncologically dangerous.

Dr. Jonathan Mercer, a urologist practicing in Chicago who specializes in men's sexual health, summarizes the current consensus plainly: "I tell patients that there is no credible evidence that sildenafil or tadalafil causes prostate cancer. The concern is understandable given how long some men take these drugs, but the data simply doesn't support it. What I do emphasize is that having ED itself — particularly when it develops at a younger age — can be an early marker of cardiovascular or metabolic conditions that warrant a thorough workup, including prostate screening appropriate for your age."

Practical Guidance for Long-Term Users

Whether you have been taking a PDE5 inhibitor for two years or twelve, the following recommendations reflect current urological best practice in the United States:

Maintain regular prostate screenings. The American Urological Association (AUA) recommends that men at average risk discuss PSA screening with their physician beginning at age 55, with earlier conversations warranted for men with a family history of prostate cancer or African American men, who face disproportionately higher risk. ED medication use does not replace or substitute for this surveillance.

Disclose all medications before PSA testing. As noted above, PDE5 inhibitors can modestly influence PSA readings. Your physician needs a complete medication list — including supplements and over-the-counter products — to interpret results accurately.

Do not self-prescribe based on online claims. The proliferation of telehealth platforms and online pharmacies has made PDE5 inhibitors more accessible than ever. Accessibility is not a substitute for medical oversight. Men taking these drugs long-term benefit from periodic check-ins with a urologist or primary care physician who can monitor for any evolving health concerns.

Report new urinary symptoms promptly. While tadalafil can improve BPH symptoms, new or worsening urinary symptoms — including difficulty initiating urination, weak stream, or blood in the urine — should never be attributed to ED medication without a proper evaluation. These symptoms can indicate prostate pathology that requires independent assessment.

Ask about combination therapy if you have BPH. If you are managing both ED and enlarged prostate symptoms, discuss with your urologist whether a daily low-dose tadalafil regimen might address both conditions simultaneously. This approach is well-supported by clinical evidence and may simplify your treatment plan.

The Bottom Line

The prostate-related fears surrounding long-term ED medication use are, by and large, not supported by the weight of clinical evidence available today. PDE5 inhibitors interact with prostate tissue — that much is true — but the nature of that interaction appears, on balance, to be neutral to mildly beneficial rather than harmful. The drugs do not cause prostate cancer, and their modest effect on PSA levels is manageable with proper clinical context.

What matters most for men who rely on these medications over the long term is not alarm, but vigilance: maintaining age-appropriate cancer screenings, communicating openly with healthcare providers, and resisting the temptation to let internet speculation override evidence-based medicine.

The prostate and the prescription can coexist — safely, and with appropriate monitoring.